Payal Gala
About Payal Gala
Payal Gala is an Associate Scientist at Nektar Therapeutics in San Francisco, California, with a focus on stem cell research and a strong background in biotechnology and bioinformatics. She has held various roles in the biotechnology sector, including positions at Sanford-Burnham Medical Research Institute, PaxVax, and Emergent BioSolutions.
Work at Nektar Therapeutics
Payal Gala has been serving as an Associate Scientist at Nektar Therapeutics since 2020. Her role involves applying her expertise in biotechnology and bioinformatics to contribute to the company's research initiatives. Nektar Therapeutics is known for its focus on innovative therapies, and Gala's work supports the development of new solutions in the biotechnology sector.
Previous Experience in Biotechnology
Prior to her current position, Payal Gala worked as a Senior Research Associate at PaxVax, Inc. from 2016 to 2020. She also held the position of Principal Associate at Emergent BioSolutions from 2018 to 2020. Earlier in her career, she gained experience as a Research Intern at Sanford-Burnham Medical Research Institute from 2014 to 2015 and as a Relationship Executive at Cryobanks International India Pvt. Ltd. from 2012 to 2013.
Education and Expertise
Payal Gala holds a Master of Science (MS) in Biotechnology and Bioinformatics with a focus on Stem Cell Research from California State University Channel Islands Extended University, which she completed from 2013 to 2015. She also earned a Bachelor's of Technology in Biotechnology from Padmashree Dr D. Y. Patil University, where she studied from 2008 to 2012. Her academic background underpins her strong skills in molecular and cellular biology.
Focus on Stem Cell Research
Gala's academic and professional focus includes stem cell research, reflecting her commitment to advancing knowledge in this critical area of biotechnology. Her expertise in both product and process development enhances her contributions to research and development projects within the biotechnology sector.